Sheridan Capital Partners backs Carolina Components Group
The Durham, North Carolina-based company supplies custom-engineered bioprocessing assemblies and ultra-pure components to more than 250 biopharmaceutical and contract manufacturing customers.
Takeaways
- Carolina Components Group is a provider of custom-engineered bioprocessing assemblies and components used in the manufacturing of biopharmaceuticals.
- Sheridan Capital Partners is acquiring Carolina Components Group.
- The target serves biopharmaceutical manufacturing across Durham, North Carolina.
Sheridan Capital Partners completed its investment in Carolina Components Group, a Durham, North Carolina-based provider of custom-engineered bioprocessing assemblies and components for biopharmaceutical manufacturing.
Founded in 2020, the company supplies ultra-pure components, single-use assemblies, and process solutions to more than 250 biopharmaceutical and contract manufacturing customers.
“CCG is the result of our multi-year thesis in the pharmaceutical manufacturing supply chain, and we are very excited to be partnering with the Company at this inflection point,” said Michael Bernard, Partner at Sheridan.
Concurrent with the transaction, Maurice Phelan was named CEO, founder John Cooling remains a meaningful owner and director, and bioprocessing veteran Maik Jornitz joins the board.
The transaction was led by Sean Dempsey, Michael Bernard, and Conor Kolstad at Sheridan Capital Partners.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.